PVLAPALVELLA THERAPEUTICS, INC.同业对比
PALVELLA THERAPEUTICS, INC. 与Pharmaceutical Preparations的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Pharmaceutical Preparations)| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PVLA本股 | $2.2B#8 | — | 10.2x#12 | 51.6x#9 | 65.3%#2 | -139.3%#13 | -90.2%#7 | -19.2%#6 | — | — | 99.0%#4 | — |
| MBX | $2.7B#1 | — | 6.5x#11 | — | — | -40.5%#11 | — | -21.2%#7 | — | — | 166.7%#1 | — |
| RCUS | $2.4B#2 | — | 5.2x#7 | 73.0x#10 | -35.3%#11 | -24.7%#10 | -1169.7%#10 | -76.1%#12 | -93.0%#9 | — | -7.0%#11 | — |
| BHVN | $2.4B#3 | — | — | — | — | 12.7%#6 | — | — | — | — | 5.1%#10 | — |
| PBH | $2.3B#4 | 13.9x#2 | 1.2x#2 | 2.2x#3 | -4.3%#9 | -11.3%#9 | 28.4%#1 | 9.9%#2 | 5.9%#3 | 4#1 | -18.2%#13 | — |
| IMNM | $2.3B#5 | — | 4.4x#5 | 332.7x#11 | -23.2%#10 | 27.5%#5 | -3228.8%#11 | -40.4%#8 | -72.8%#7 | — | 19.4%#8 | — |
| XNCR | $2.3B#6 | — | 4.5x#6 | 18.2x#6 | 13.7%#6 | 60.5%#2 | -141.4%#8 | -18.3%#5 | -31.5%#5 | — | 120.4%#2 | — |
| VERA | $2.2B#7 | — | 5.4x#9 | — | — | -96.9%#12 | — | -73.5%#11 | -72.7%#6 | — | 18.5%#9 | — |
| PRGO | $2.2B#9 | — | 0.9x#1 | 0.5x#1 | -2.8%#8 | -729.7%#15 | -26.4%#4 | -56.7%#10 | -20.9%#4 | 4#1 | -18.0%#12 | 7.3%#1 |
| HRMY | $2.2B#10 | 12.0x#1 | 2.2x#4 | 2.5x#4 | 21.5%#5 | 9.1%#8 | 24.0%#2 | 15.9%#1 | 25.5%#1 | 4#1 | 26.2%#7 | — |
| ZYME | $2.1B#11 | — | 26.6x#13 | 20.2x#7 | 38.9%#4 | 33.9%#3 | -87.3%#6 | -100.9%#13 | — | — | 59.5%#5 | — |
| SEPN | $2.0B#12 | — | 5.3x#8 | 44.4x#8 | 4174.5%#1 | 31.9%#4 | -148.6%#9 | -12.6%#3 | — | — | 118.1%#3 | — |
| TRVI | $2.0B#13 | — | 6.1x#10 | — | — | 10.7%#7 | — | -13.3%#4 | — | — | 29.6%#6 | — |
| SRPT | $2.0B#14 | — | 1.3x#3 | 1.1x#2 | 4.3%#7 | -403.3%#14 | -37.5%#5 | -46.7%#9 | -73.0%#8 | — | -24.2%#14 | — |
| BRVE | $1.9B#15 | — | — | — | — | — | — | — | — | — | — | — |
| XERS | $1.9B#16 | — | — | 6.5x#5 | 43.7%#3 | 101.0%#1 | 8.5%#3 | — | 20.6%#2 | — | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-11-04。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议